Ola Niewiadomski

Dr. Ola Niewiadomski


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2016 in Internal Medicine Journal
Verified
Journal Article
Closed access
PDF file
ONOla Niewiadomski
Ola Niewiadomski
CSC. Studd
C. Studd
JWJ. Wilson
J. Wilson
JWJ. Williams
J. Williams
CHC. Hair
C. Hair
SBS. Bell
S. Bell

27 September 2020 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
EFEmma Flanagan
Emma Flanagan
PGPeter R. Gibson
Peter R. Gibson
EWEmily K. Wright
Emily K. Wright
GMGregory Thomas Moore
Gregory Thomas Moore
MSMiles Sparrow
Miles Sparrow
TGThe PICCOLO Study Group
The PICCOLO Study Group
Summary: Background: The impact of pregnancy on levels of biologic agents in patients with IBD is undefined and time to elimination in vedolizumab‐exposed infants is unknown.Aims: To determine the effect of pregnancy on infliximab, adalimumab and vedolizumab levels and to study infant vedolizumab clearanceMethods: In a prospective observational study, maternal drug levels were measured pre‐conception, in each trimester, at delivery and postpartum. The association between drug levels and gestation in weeks was assessed using generalised estimating equation modelling. Infant vedolizumab levels were performed at birth (cord blood), 6 weeks and 3 months or until undetectable.Results: We included 50 IBD patients (23 on infliximab, 15 on adalimumab and 12 on vedolizumab) with at least two intrapartum observations, plus 5 patients on vedolizumab with only mother and baby samples at delivery. Modelling showed no change in adalimumab levels, an increase in infliximab levels of 0.16 (95% CI 0.08‐0.24) µg/L/week (P < 0.001) and a decrease of 0.18 (95% CI: −0.33 to −0.02) µg/L/week (P = 0.03) for vedolizumab. In 17 mother‐baby pairs, median infant vedolizumab levels at birth were lower than maternal levels (P < 0.05) with an infant:maternal ratio of 0.7 (IQR 0.5‐0.9). Vedolizumab was undetectable between 15 and 16 weeks of age in all 12 infants completing follow‐up testing.Conclusions: During pregnancy, adalimumab levels remain stable, while infliximab levels increase and vedolizumab levels decrease. However, the increments were small suggesting that intrapartum therapeutic drug monitoring and dose adjustment are not indicated. Unlike infliximab and adalimumab, infant vedolizumab levels are lower in cord blood than in mothers and appear to clear rapidly.

31 May 2017 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
JBJohan Burisch
Johan Burisch
ZVZsuzsanna Vegh
Zsuzsanna Vegh
KKKonstantinnos H Katsanos
Konstantinnos H Katsanos
DCDimitrios K Christodoulou
Dimitrios K Christodoulou
DLDaniela Cornelia Lazar
Daniela Cornelia Lazar
JDJens Frederik Dahlerup
Jens Frederik Dahlerup
Anaemia is an important complication of inflammatory bowel disease [IBD]. The aim of this study was to determine the prevalence of anaemia and the practice of anaemia screening during the first year following diagnosis, in a European prospective population-based inception cohort. Newly diagnosed IBD patients were included and followed prospectively for 1 year in 29 European and one Australian centre. Clinical data including demographics, medical therapy, surgery and blood samples were collected. Anaemia was defined according to the World Health Organization criteria. A total of 1871 patients (Crohn’s disease [CD]: 686, 88%; ulcerative colitis [UC]: 1,021, 87%; IBD unclassified [IBDU] 164. 81%) were included in the study. The prevalence of anaemia was higher in CD than in UC patients and, overall, 49% of CD and 39% of UC patients experienced at least one instance of anaemia during the first 12 months after diagnosis. UC patients with more extensive disease and those from Eastern European countries, and CD patients with penetrating disease or colonic disease location, had higher risks of anaemia. CD and UC patients in need of none or only mild anti-inflammatory treatment had a lower risk of anaemia. In a significant proportion of patients, anaemia was not assessed until several months after diagnosis, and in almost half of all cases of anaemia a thorough work-up was not performed. Overall, 42% of patients had at least one instance of anaemia during the first year following diagnosis. Most patients were assessed for anaemia regularly; however, a full anaemia work-up was frequently neglected in this community setting.

30 April 2024 in Intestinal Research
Verified
Journal Article
Open access
PDF file
ABAnuj Bohra
Anuj Bohra
DCDeclan Connoley
Declan Connoley
DCDanny Con
Danny Con
Jonathan SegalJonathan Segal
Jonathan Segal
ONOla Niewiadomski
Ola Niewiadomski
NKNuman Kutaiba
Numan Kutaiba
Background/Aims: Assessment of quality of magnetic resonance enterography (MRE) in small bowel Crohn’s disease (CD) activity evaluation has received little attention. We assessed the impact of bowel distention and motion artifact on MRE activity indices in ileal CD.Methods: A cohort of patients who underwent contemporaneous MRE and colonoscopy for ileal CD assessment between 2014 and 2021 at 2 centers were audited. An abdominal radiologist blinded to clinical data reviewed each MRE, graded bowel distention and motion artifact upon a pre-specified 3-point scale and calculated the original magnetic resonance index of activity (MaRIA) and simplified MaRIA (sMaRIA), London index and CD MRE index (CDMI). Ileal endoscopic activity was graded via the Simplified Endoscopy Score for CD (SES-CD). The performance of MRE indices in discriminating active disease (SES-CD ≥3) stratified by MRE quality was measured by receiver operator characteristic analyses.Results: One hundred and thirty-seven patients had MRE and colonoscopy within a median of 16 days (range, 0–30 days) with 63 (46%) exhibiting active disease (SES-CD ≥3). Forty-four MREs (32%) were deemed low quality due to motion artifact and/or moderate to poor distention. Low-quality MREs demonstrated reduced discriminative performance between ileal SES-CD ≥3 and MRE indices (MaRIA 0.838 vs. 0.634, sMaRIA 0.834 vs. 0.527, CDMI 0.850 vs. 0.595, London 0.748 vs. 0.511, P<0.05 for all). Individually the presence of any motion artifact markedly impacted the discriminative performance (e.g., sMaRIA area under the curve 0.544 vs. 0.814, P<0.05).Conclusions: Image quality parameters can significantly impact MRE disease activity interpretation. Quality metrics should be reported, enabling cautious interpretation in lower-quality studies.

21 June 2023 in Internal Medicine Journal
Verified
Journal Article
Open access
DTDaniel Tassone
Daniel Tassone
CBChamara Basnayake
Chamara Basnayake
EWEmily Wright
Emily Wright
MLMark Lust
Mark Lust
MKMichael A Kamm
Michael A Kamm
NDNik S. Ding
Nik S. Ding
Background: Patients with inflammatory bowel disease (IBD) are at increased risk of malignancy and infection compared to the general population.Aims: We aim to identify risk factors for malignancy or serious infection in our IBD cohort.Methods: Patients with IBD from a single tertiary referral centre were included. Demographic and clinical details, including immunosuppressant exposure, were collected and medical records retrospectively screened for adverse events, including malignancy or infection requiring hospitalisation. Logistic regression was used to evaluate risk factors for adverse events.Results: Five hundred and forty‐nine patients with IBD (340 Crohn disease (CD) and 209 ulcerative colitis (UC)) were studied. Forty‐eight malignancies, including 39 (81.3%) non‐melanoma skin cancers, 3 (6.3%) haematologic malignancies and 6 (15.4%) solid‐organ malignancies, were identified, and 92 cases of serious infection were detected. IBD duration (odds ratio (OR) = 1.08; 95% confidence interval (CI) = 1.03–1.13) and ileocolonic CD (OR = 4.96; 95% CI = 1.13–21.71) were associated with increased odds of overall cancer. Compared with patients not previously exposed to the given class of immunosuppression assessed, the development of overall malignancy was not higher with thiopurine exposure (OR = 1.00; 95% CI = 0.50–2.24) or anti‐tumour necrosis factor‐alpha (TNF‐α) exposure (OR = 0.78; 95% CI = 0.37–1.64). Similarly, compared with patients not exposed, infection risk was not affected by thiopurine (OR = 0.74; 95% CI = 0.46–1.20) or anti‐TNF exposure (OR = 0.60; 95% CI = 0.38–0.95).Conclusions: Factors including ileocolonic CD and increasing IBD duration were associated with higher malignancy risk in this cohort. Compared with non‐exposure, patients exposed to thiopurines were not at increased risk of malignancy or serious infection. Similarly, patients exposed to anti‐TNF treatment did not experience increased rates of malignancy or serious infection compared to patients not exposed to this treatment.

6 May 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
GTGina Trakman
Gina Trakman
ERErin E. Russell
Erin E. Russell
AHAmy L. Hamilton
Amy L. Hamilton
AWAmy L. Wilson-O’Brien
Amy L. Wilson-O’Brien
ETEmily Thompson
Emily Thompson
MKMichael A Kamm
Michael A Kamm
Background/Objectives: Exclusive Enteral Nutrition (EEN) and the Crohn’s Disease Exclusion Diet (CDED) have been shown to induce remission in Crohn’s disease. Low-sulphur, plant-based diets are being explored for ulcerative colitis, and wholefood, low-additive approaches are emerging as significant. Although Inflammatory Bowel Disease (IBD) patients modify their diet, evidence for tolerability and benefit outside clinical trials is limited. The DELECTABLE program aimed to assess satisfaction, adherence, and efficacy of dietary therapies as part of IBD care. Methods: In this dietitian-led, open-label, prospective study, patients with Crohn’s disease were offered the CDED or a whole-food, additive-free diet (WFD), and patients with ulcerative colitis were offered a low-sulphur, plant-based diet (UCD) or WFD. Primary outcomes were 12-week diet satisfaction (modified DSAT-28) and diet adherence, including food additive intake. Secondary outcomes were quality of life (QoL) (IBDQ-9), disease activity (CDAI for Crohn’s disease, partial Mayo score for ulcerative colitis), and biochemical markers (CRP, faecal calprotectin). Analyses were conducted within, rather than between, diet arms due to the non-random nature of the study. Diet adherence and disease activity change across time points (baseline, week 6, week 12) were assessed using repeated measures ANOVA or Friedman’s test, with pairwise paired t-test or Wilcoxon Signed-Rank test. Diet satisfaction and quality of life changes across time (baseline/week 1, week 12) were assessed using a paired t-test or Wilcoxon Signed-Rank test. Results: Of 165 referrals, 76 patients enrolled, with 64 completing the 12-week program (CDED: n = 15, WFD: n = 42, UCD: n = 7). Diet satisfaction was initially high and remained stable over time on CDED (p = 0.212) and improved on WFD (p = 0.03). Patient- and dietitian-rated adherence was high at baseline and did not significantly decrease on any diet arm (p > 0.349). Food additive intake decreased on WFD (p = 0.009). QoL improved on CDED and WFD (p < 0.001). CRP, calprotectin, and CDAI were reduced on CDED (p < 0.045), and CDAI and partial Mayo were reduced on WFD (p < 0.027). Conclusions: Well-balanced therapeutic diets are feasible and well-accepted by patients with IBD, with a promising impact on disease activity.